AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
Leader of Series B-2 Financing Round Matthew Katz Joins AIVITA’s Board of Directors IRVINE, Calif., Feb. 25, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a biotechnology company (the “Company”) specializing in innovative stem cell applications, announced today the first closing of its $25 million Series B-2 preferred stock investment round. The first closing of $12.5 million was … Continued